Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Ce...
September 19 2019 - 8:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer
of cell-based technologies and therapeutics, today announced it has
initiated its first-in-human, Phase I clinical trial of CD19
Chimeric Antigen Receptor (CAR)-T candidate, AVA-001, at the Hebei
Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China.
The clinical trial will interrogate the treatment of
relapsed/refractory B-cell malignancies, including B-cell
lymphoblastic leukemia (B-ALL) and non-Hodgkin’s Lymphoma (NHL).
CAR-T cells are engineered to express a receptor (CAR) that
recognizes a specific cancer surface target to attack. Unlike
traditional small molecule or biologic treatments, the autologous
CAR-T therapies are specifically manufactured for each individual
patient. AVA-001 was designed to provide a more powerful,
personalized CAR delivery mechanism.
Co-developed with China Immunotech Co. Ltd., AVA-001 is
considered to be a second-generation CAR-T using the 4-1BB (CD137),
a co-stimulatory signaling pathway, which exhibited strong
anti-cancer activity during the pre-clinical study. It is also
expected to feature a shorter bio-manufacturing time.
The production process starts with the extraction of T cells
from an individual patient, which are then converted into CAR-T
cells that are specifically targeted to recognize and destroy
cancer cells. The Company anticipates AVA-001 will entail a
shortened bio-production cycle, which could potentially empower the
clinicians to provide accelerated treatment to patients with
hematologic malignancies. Avalon is expected to recruit 20
patients for clinical safety and efficacy monitoring and assessment
(under registered clinical trial number NCT03952923 and hospital
study ID number LDP-C-001).
“We have successfully evolved into an active clinical-stage
company with a primary focus on immune effector cell therapy in the
oncology domain. As our first-in-human clinical trial, the study of
AVA-001 marks a significant milestone for Avalon. We are
committed to delivering precise clinical execution and leadership
in cell-based therapeutics with a strong pipeline of additional
cellular immunotherapy candidates,” stated David Jin, M.D., Ph.D.,
President, Chief Executive Officer and Co-founder of Avalon.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative exosome technologies and
cellular therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth,
development, as well as competitiveness in healthcare and CellTech
industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of in vitro
diagnostics (''liquid biopsy''), immune effector cell therapy
(including CAR-T/CAR-NK), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements Certain statements
contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare Corp.4400
Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications,
LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024